Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: Extended analysis of the PROSE trial

被引:24
作者
Hornberger, John [1 ,2 ]
Hirschc, Fred R. [3 ,4 ]
Li, Qianyi [2 ]
Page, Ray D. [5 ]
机构
[1] Stanford Univ, Sch Med, Dept Internal Med, Stanford, CA 94305 USA
[2] Cedar Associates LLC, Menlo Pk, CA 94025 USA
[3] Univ Colorado, Colorado Canc Ctr, Dept Med, Aurora, CO 80045 USA
[4] Univ Colorado, Colorado Canc Ctr, Dept Pathol, Aurora, CO 80045 USA
[5] Ctr Canc & Blood Disorders, Ft Worth, TX 76104 USA
关键词
Non-small cell lung cancer; Erlotinib; Proteomic test; Economics; Cost-effectiveness; Chemotherapy; 2ND-LINE TREATMENT; MASS-SPECTROMETRY; CLINICAL-TRIALS; ERLOTINIB; CHEMOTHERAPY; THERAPY; BEVACIZUMAB; UTILITIES; DOCETAXEL; VERISTRAT;
D O I
10.1016/j.lungcan.2015.03.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: Lung cancer accounts for a significant number of new cancer cases and deaths, with the majority of patients presenting with non-small cell lung cancer (NSCLC). Although epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors are recommended as an alternative to chemotherapy for certain patients, challenges exist for clinical utilization. The objective of this analysis was to assess the outcome and economic implications of a clinically validated serum-based proteomic test to guide treatment decisions in patients with advanced NSCLC, who are EGFR-negative or status unknown, and have progressed following at least one chemotherapy regimen. Methods:This analysis was conducted from a US payer perspective. Clinical outcomes were evaluated over the lifetime of a patient, based on data from randomized trials and clinical studies. The clinical endpoints included treatment utilization, adverse events, survival, and a composite measure of length and quality of life, referred to as the quality-adjusted life year (QALY). Costs for testing, treatment, surveillance, and management of adverse events were analyzed based on publicly available costs of the related procedures. The economic endpoints were cumulative lifetime direct medical costs and cost per QALY gained. Results: In the base case, treatment recommendation for 27.3% of the patient population changed from erlotinib to chemotherapy after using the proteomic test. Overall survival increased by 0.091 year and QALYs increased by 0.050 year. The total lifetime direct medical cost per patient decreased by $135 with test-guided treatment. The findings were robust over a wide range of variation in the input parameters. Conclusion: The serum-based proteomic test informed treatment selection for patients with advanced NSCLC who failed previous chemotherapy regimen(s), improving QALYs and saving costs. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:223 / 230
页数:8
相关论文
共 35 条
[1]   A phase II study of bevacizumab and erlotinib as initial treatment for metastatic non-squamous, non-small cell lung cancer with serum proteomic evaluation [J].
Akerley, Wallace ;
Boucher, Kenneth ;
Rich, Nathan ;
Egbert, Lyle ;
Harker, Graydon ;
Bylund, Julie ;
Van Duren, Terry ;
Reddy, Chakravarthy .
LUNG CANCER, 2013, 79 (03) :307-311
[2]   The impact of a serum based proteomic mass spectrometry test on treatment recommendations in advanced non-small-cell lung cancer [J].
Akerley, Wallace L. ;
Nelson, Richard E. ;
Cowie, Robin H. ;
Spinella, Dominic G. ;
Hornberger, John .
CURRENT MEDICAL RESEARCH AND OPINION, 2013, 29 (05) :517-525
[3]  
American Cancer Society, LUNG CANC NONSM CELL
[4]  
American Cancer Society, 2014, CANC FACTS FIG 2014
[5]  
[Anonymous], CONS PRIC IND ALL UR
[6]  
[Anonymous], 2015, CLIN PRACT GUID ONC
[7]   Evaluating the total costs of chemotherapy-induced toxicity: Results from a pilot study with ovarian cancer patients [J].
Calhoun, EA ;
Chang, CH ;
Welshman, EE ;
Fishman, DA ;
Lurain, JR ;
Bennett, CL .
ONCOLOGIST, 2001, 6 (05) :441-445
[8]   Prognostic and Predictive Role of the VeriStrat Plasma Test in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Erlotinib or Placebo in the NCIC Clinical Trials Group BR.21 Trial [J].
Carbone, David P. ;
Ding, Keyue ;
Roder, Heinrich ;
Grigorieva, Julia ;
Roder, Joanna ;
Tsao, Ming-Sound ;
Seymour, Lesley ;
Shepherd, Frances A. .
JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (11) :1653-1660
[9]   VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab [J].
Carbone, David P. ;
Salmon, J. Stuart ;
Billheimer, Dean ;
Chen, Heidi ;
Sandler, Alan ;
Roder, Heinrich ;
Roder, Joanna ;
Tsypin, Maxim ;
Herbst, Roy S. ;
Tsao, Anne S. ;
Tran, Hai T. ;
Dang, Thao P. .
LUNG CANCER, 2010, 69 (03) :337-340
[10]   Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) [J].
Carlson, Josh J. ;
Reyes, Carolina ;
Oestreicher, Nina ;
Lubeck, Deborah ;
Ramsey, Scott D. ;
Veenstra, David L. .
LUNG CANCER, 2008, 61 (03) :405-415